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Association of reduced red
blood cell deformability and
diabetic nephropathy
To the Editor: In a recent issue of Kidney International,
Brown et al [1] reported significant data concerning red
blood cell deformability and and renal function decline
in type 2 diabetic patients. They propose a smart phys-
iopathologic explanation using the “AGEs” hypothesis
that seems relevant and convincing. However, one can
suppose that AGEs are not the only pathway involved in
both reduction of red blood cell deformability and pro-
gression of renal failure in this population. Indeed, red
blood cell deformability is reduced in diabetic patients [2,
3]. This reduction is correlated with a decrease in Na,K-
ATPase activity in red blood cells. The reduction of both
Na,K-ATPase activity and red blood cell deformability is
proportional to the simultaneous decrease in C-peptide
plasma concentration in type 2 diabetic patients [4] and
can be corrected by C-peptide administration [5]. Besides
being related to NO-mediated direct effects on the re-
sistance vessels, C-peptide’s circulatory effects involve
rheologic factors. This effect is blockable by ouabain,
indicating that it is mediated in part by a restoration
of erytheocyte Na,K-ATPase activity [6]. Furthermore,
C-peptide is involved in stimulation of eNOS in renal
capillary endothelial cells [7], which may modify the
glomerular function, including diminished albumin ex-
cretion. Improved renal function may also be a con-
sequence of stimulation by C-peptide of glomerular or
tubular Na+, K+-ATPase activity [8, 9]. Last, but not
least, a clinical study of a large cohort of type 2 dia-
betic patients showed that onset of diabetic nephropathy
was correlated with the residual plasma C-peptide levels
[10]. Altogether, these are strong arguments to complete
Brown’s “AGEs” hypothesis by measuring C-peptide lev-
els in a future study in this population.
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Reply from the Authors
We wish to thank Rebsomen and Tsimaratos for their
interest in our study, and would like to respond to points
raised in their letter to the Editor. While we recognize
that Na,K-ATPase activity influences RBC deformability
(RBC-df), and that basal plasma C-peptide concentration
has a beneficial effect on RBC-df by a mechanism involv-
ing Na,K-ATPase [1], we do not believe that C-peptide
deficiency plays a role in our study.
The effect of absolute C-peptide deficiency on RBC-df
has been reported in type 1 diabetic subjects [2]. Fur-
thermore, significantly reduced (but not absent) levels of
C-peptide have been shown to occur only in type 2 di-
abetic subjects who require insulin treatment, and that
C-peptide levels are normal in type 2 subjects who do not
require insulin for glucose control. All diabetic subjects in
our study were type 2, and none required insulin to con-
trol blood glucose. We measured RBC-df in two groups
of nondiabetic subjects with renal disease who served as
control. In these nondiabetic control subjects there was
significant impairment in RBC-df. In fact, impairment in
RBC-df in these subjects with end-stage renal disease (on
maintenance hemodialysis) was not different from their
diabetic counterparts.
Although C-peptide was not measured in our study, we
presume that its concentration was not deficient in either
our nondiabetic control or non–insulin-requiring type 2
diabetic subjects.
